"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03799718","Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS",,"Completed","No Results Available","Multiple Sclerosis, Chronic Progressive","Biological: NurOwn (MSC-NTF cells)","Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCT-101-US","March 13, 2019","March 11, 2021","March 30, 2021","January 10, 2019",,"September 1, 2021","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03799718"
2,"NCT01051882","Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT)","Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-001-HMO-CTIL","June 2011","December 2012","March 2013","January 20, 2010",,"January 10, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01051882"
3,"NCT02017912","Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS","NurOwn","Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: Autologous MSC-NTF cells|Biological: Placebo","Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BCT-001-US","May 2014","March 2016","July 2016","December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02017912"
4,"NCT03280056","Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration","To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers","Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM)","All","18 Years to 60 Years   (Adult)","Phase 3","263","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCT-002-US","August 28, 2017","October 30, 2020","October 30, 2020","September 12, 2017",,"October 6, 2021","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03280056"
5,"NCT01777646","Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF","Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","14","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-002-HMO-CTIL","December 2012","September 2014","September 2015","January 29, 2013",,"March 8, 2018","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01777646"
